skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR'alfa'
Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR'alfa'
Material Type:
Artigo 		Adicionar ao Meu Espaço

Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR'alfa'

Mahadeo Sukhai Xuemei Wu; Yali Xuan; Tong Zhang; Patrícia P Reis; Karina Dubé; Eduardo Magalhães Rego; Mantu Bhaumik; Denis J Bailey; Suzanne Kamel-Reid; Pier Paolo Pandolfi; Richard A Wells

Oncogene London, 2004 v. 23, p. 665-678, 2004

London 2004

Localização: FMRP - Fac. Medicina de Ribeirão Preto    (pcd 1434507 )(Acessar)

2
Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR'alfa'
Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR'alfa'
Material Type:
Artigo 		Adicionar ao Meu Espaço

Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR'alfa'

Mahadeo Sukhai Xuemei Wu; Yali Xuan; Tong Zhang; Patrícia P Reis; Karina Dubé; Eduardo Magalhães Rego; Mantu Bhaumik; Denis J Bailey; Suzanne Kamel-Reid; Pier Paolo Pandolfi; Richard A Wells

Oncogene London, 2004 v. 23, p. 665-678, 2004

London 2004

Localização: FMRP - Fac. Medicina de Ribeirão Preto    (pcd 1434507 )(Acessar)

3
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
Material Type:
Artigo 		Adicionar ao Meu Espaço

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Hughes, T P ; Leber, B ; Cervantes, F ; Spector, N ; Pasquini, R ; Clementino, N C D ; Schwarer, A P ; Dorlhiac-Llacer, P E ; Mahon, F-X ; Rea, D ; Guerci-Bresler, A ; Kamel-Reid, S ; Bendit, I ; Acharya, S ; Glynos, T ; Dalal, D ; Branford, S ; Lipton, J H

Leukemia, 2017-11, Vol.31 (11), p.2529-2531 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
4
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

Rodriguez-Freixinos, V. ; Lheureux, S. ; Mandilaras, V. ; Clarke, B. ; Dhani, N.C. ; Mackay, H. ; Butler, M.O. ; Wang, L. ; Siu, L.L. ; Kamel-Reid, S. ; Stockley, T. ; Bedard, P.L. ; Oza, A.M.

Gynecologic oncology, 2019-05, Vol.153 (2), p.304-311 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
5
Use of cytological samples of metastatic melanoma for ancillary studies
Use of cytological samples of metastatic melanoma for ancillary studies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Use of cytological samples of metastatic melanoma for ancillary studies

Ko, H. M. ; Saieg, M. A. ; Cunha Santos, G. ; Kamel‐Reid, S. ; Boerner, S. L. ; Geddie, W. R.

Cytopathology (Oxford), 2017-06, Vol.28 (3), p.221-227 [Periódico revisado por pares]

England: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
6
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy

Kim, D.H. ; Xu, W. ; Kamel-Reid, S. ; Liu, X. ; Jung, C.W. ; Kim, S. ; Lipton, J.H.

Annals of oncology, 2010-06, Vol.21 (6), p.1179-1188 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS
Material Type:
Artigo 		Adicionar ao Meu Espaço

Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS

Vincent, M D ; Kuruvilla, M S ; Leighl, N B ; Kamel-Reid, S

Current oncology (Toronto), 2012-06, Vol.19 (Suppl 1), p.S33-44 [Periódico revisado por pares]

Canada: Multimed Inc

Texto completo disponível

Citações Citado por
8
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer

Lim, C. ; Tsao, M.S. ; Le, L.W. ; Shepherd, F.A. ; Feld, R. ; Burkes, R.L. ; Liu, G. ; Kamel-Reid, S. ; Hwang, D. ; Tanguay, J. ; da Cunha Santos, G. ; Leighl, N.B.

Annals of oncology, 2015-07, Vol.26 (7), p.1415-1421 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation
Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation

Ong, M ; Kwan, K ; Kamel-Reid, S ; Vincent, M

Current oncology (Toronto), 2012-06, Vol.19 (3), p.e222-226 [Periódico revisado por pares]

Canada: Multimed Inc

Texto completo disponível

Citações Citado por
10
Benefits, issues, and recommendations for personalized medicine in oncology in Canada
Benefits, issues, and recommendations for personalized medicine in oncology in Canada
Material Type:
Artigo 		Adicionar ao Meu Espaço

Benefits, issues, and recommendations for personalized medicine in oncology in Canada

Butts, C ; Kamel-Reid, S ; Batist, G ; Chia, S ; Blanke, C ; Moore, M ; Sawyer, M B ; Desjardins, C ; Dubois, A ; Pun, J ; Bonter, K ; Ashbury, F D

Current oncology (Toronto), 2013-10, Vol.20 (5), p.e475-483 [Periódico revisado por pares]

Canada: Multimed Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (421)
  2. Reports  (6)
  3. Book Chapters  (2)
  4. Imagens  (1)
  5. Conjunto de Dados  (1)
  6. Mais opções open sub menu

Autor/Criador 

  1. Xuan, Y  (2)
  2. Reis, P  (2)
  3. Zhang, T  (2)
  4. Wu, X  (2)
  5. Sukhai, M  (2)
  6. Bhaumik, M  (2)
  7. Wells, R  (2)
  8. Kamel-Reid, S  (2)
  9. Dubé, K  (2)
  10. Pandolfi, P  (2)
  11. Bailey, D  (2)
  12. Rego, E  (2)
  13. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1995  (21)
  2. 1995Até2001  (26)
  3. 2002Até2008  (86)
  4. 2009Até2016  (199)
  5. Após 2016  (99)
  6. Mais opções open sub menu

Idioma 

  1. Japonês  (40)
  2. Alemão  (1)
  3. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Xuan, Y
  2. Reis, P
  3. Zhang, T
  4. Wu, X
  5. Sukhai, M

Neste Assunto:

  1. Science & Technology
  2. Life Sciences & Biomedicine
  3. Humans
  4. Oncology
  5. Female

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.